Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies

Diabetes, Obesity and Metabolism

Volumn 18, Issue 9, 2016, Pages 945-948

  Apovian, C ^a   Palmer, K ^a   Fain, R ^b   Perdomo, C ^b   Rubino, D ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EISAI INC   (United States)

^c Washington Center for Weight Management and Research   (United States)

Author keywords

antiobesity drug; appetite control; body composition; clinical trial; obesity therapy

Indexed keywords

LORCASERIN; PLACEBO; BENZAZEPINE DERIVATIVE; SEROTONIN 2 AGONIST; SEROTONIN 2C RECEPTOR;

BODY MASS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; LEAN BODY WEIGHT; LETTER; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION; ADIPOSE TISSUE; ADULT; BODY COMPOSITION; CASE CONTROL STUDY; COMPLICATION; DIAGNOSTIC IMAGING; DIET THERAPY; FEMALE; KINESIOTHERAPY; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVERWEIGHT; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; BENZAZEPINES; BODY COMPOSITION; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET THERAPY; EXERCISE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 84977156910     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12690     Document Type: Letter

References (15)

1. Neeland IJ, Turer AT, Ayers CR et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012; 308: 1150–1159.
2. Neeland IJ, Turer AT, Ayers CR et al. Body fat distribution and incident cardiovascular disease in obese adults. J Am Coll Cardiol 2015; 65: 2150–2151.
3. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48.
4. Ravussin E, Burnand B, Schutz Y, Jequier E. Twenty-four-hour energy expenditure and resting metabolic rate in obese, moderately obese, and control subjects. Am J Clin Nutr 1982; 35: 566–573.
5. Miller CT, Fraser SF, Levinger I et al. The effects of exercise training in addition to energy restriction on functional capacities and body composition in obese adults during weight loss: a systematic review. PLoS One 2013; 8: e81692.
6. Stelmach-Mardas M, Mardas M, Walkowiak J, Boeing H. Long-term weight status in regainers after weight loss by lifestyle intervention: status and challenges. Proc Nutr Soc 2014; 73: 509–518.
7. Franz MJ, VanWormer JJ, Crain AL et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007; 107: 1755–1767.
8. Smith SR, Weissman NJ, Anderson CM et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245–256.
9. Fidler MC, Sanchez M, Raether B et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067–3077.
10. O'Neil PM, Smith SR, Weissman NJ et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012; 20: 1426–1436.
11. BELVIQ (lorcaserin hydrochloride) US Prescribing Information. Eisai, Woodcliff Lake, NJ, 2014.
12. Bays H. Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 2014; 21: 345–351.
13. Gotfredsen A, Westergren HH, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 2001; 25: 1154–1160.
14. Li CJ, Yu Q, Yu P et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol 2014; 13: 36.
15. Smith SR, Fujioka K, Gupta AK et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 2013; 15: 863–866.